Larimar Therapeutics (LRMR.O): Regulatory Clarity, Durable Efficacy, & Manageable Safety Drive Attractive Risk/Reward - Buyers on Weakness

Research evidence excerpt

Larimar Therapeutics (LRMR.O): Regulatory Clarity, Durable Efficacy, & Manageable Safety Drive Attractive Risk/Reward - Buyers on Weakness

Flash |

29 Jun 2026 13:01:27 ET │ 11 pages

Larimar Therapeutics (LRMR.O)

Regulatory Clarity, Durable Efficacy, & Manageable Safety Drive

Attractive Risk/Reward - Buyers on Weakness

CITI'S TAKE Buy / High Risk

Price (26 Jun 26 16:00) US$3.66 We come away constructive following Larimar's update, with the most

Target price US$14.00 important takeaway being clear FDA feedback that the current data

package is sufficient to support a BLA submission under accelerated Expected share price return 282.5%

approval. Larimar has initiated a rolling submission, with the first module Expected dividend yield 0.0%

already submitted and completion of the remaining modules expected in Expected total return 282.5%

2H26, along with an expectation for priority review. Efficacy continues to Market Cap US$380M

be encouraging with longer follow-up and a larger dataset, showing

significant and consistent positive trends on outcomes measures versus

natural history. The positive correlation between frataxin increase with

improvement in outcomes is directionally positive, providing further Samantha Semenkow, Ph.D.AC

mechanistic validation. On safety, we continue to believe the concerns on +1-716-730-7388

the the risk of anaphylaxis and the discontinuation rate are overblown, samantha.semenkow@citi.com

and Dr. Marshall Summar, a KOL on the call, emphasized a favorable Benjamin E. Paluch,Ph.D.

benefit/risk profile. Taken together, we see favorable risk/reward from +1-716-730-8388

current valuation and are buyers on today's weakness. benjamin.paluch@citi.com

Longer-term data strengthens efficacy profile - The updated open-label dataset